Structural Biology & Molecular Modeling Techniques Market by Technique (Computational Modeling, Cryo-Em, Mass Spectrometry), Product Type (Instruments, Reagents And Consumables, Services), Workflow Step, Application, End User - Global Forecast 2025-2032
Description
The Structural Biology & Molecular Modeling Techniques Market was valued at USD 11.10 billion in 2024 and is projected to grow to USD 13.20 billion in 2025, with a CAGR of 18.86%, reaching USD 44.24 billion by 2032.
A unified overview of how integrated experimental and computational advances are redefining structural biology practice and accelerating translational research outcomes
The structural biology and molecular modeling landscape is undergoing a rapid evolution driven by converging advances in computational power, cryo-electron microscopy, mass spectrometry, nuclear magnetic resonance, and crystallography. Researchers and technology adopters are no longer operating within siloed technique domains; instead, integrated workflows that combine high-resolution imaging, precise mass analysis, and predictive in silico modeling are establishing new norms for how molecular structures are resolved and functionally interpreted. This synthesis of experimental and computational approaches is enabling deeper mechanistic understanding across basic biology, translational research, and therapeutic design.
As academic groups, biotechnology ventures, contract research organizations, and pharmaceutical developers increasingly demand interoperable data and reproducible methods, the pressure to harmonize instrumentation, reagents, software, and standardized workflows is intensifying. The industry is responding with modular platforms, cloud-enabled processing pipelines, and cross-disciplinary teams that accelerate the translation of structural insights into actionable hypotheses. Consequently, leadership in this field now depends as much on data engineering and computational governance as on hardware performance and reagents quality.
How convergent innovations in imaging, analytical chemistry, and predictive computing are reshaping laboratory operations and translational research pipelines
The past several years have witnessed transformative shifts in capabilities and expectations across structural biology and molecular modeling. Advances in single-particle cryo-electron microscopy have simplified access to near-atomic resolution for complex proteins, while improvements in detector sensitivity and sample preparation methods have reduced the barrier to entry for smaller laboratories. Parallel progress in mass spectrometry, including refined ionization techniques and instrument automation, has improved confidence in proteoform identification and post-translational modification mapping. Meanwhile, enhancements in NMR hardware and pulse sequences have broadened the applicability of solution and solid-state analyses for challenging systems.
On the computational side, increased adoption of molecular dynamics, homology modeling, and ab initio prediction tools has shifted many early-stage structural questions into in silico domains, enabling hypothesis generation prior to experimental commitment. Integration across single-particle analysis, tomography, and computational docking has created hybrid workflows that shorten iteration cycles between model and experiment. These shifts are accompanied by organizational changes: multidisciplinary teams that combine wet-lab expertise with data science and software engineering are becoming essential for executing complex projects at scale. Collectively, these developments are changing investment priorities and operational models across academia and industry, and they are elevating the importance of software interoperability, data standards, and reproducible pipelines.
Assessment of how 2025 tariff adjustments have reshaped procurement, supply chain resilience, and strategic sourcing for structural biology stakeholders
Policy changes in tariffs and trade barriers implemented in 2025 have exerted measurable pressure on procurement, supply chain strategies, and capital planning for entities engaged in structural biology and molecular modeling. Increased duties on imported high-value instruments and specialty reagents have prompted manufacturers and distributors to re-evaluate sourcing strategies and pricing models, resulting in longer lead times for certain instrument deliveries and a renewed emphasis on regional supplier diversification. Academic and industry laboratories dependent on specific consumables have had to balance short-term inventory pre-positioning against the operational risk of excess stock, while contract research organizations with thin margins have sought to renegotiate supplier terms or consolidate vendor relationships.
These policy shifts have also accelerated localization initiatives, with some manufacturers expanding regional manufacturing footprints or forging assembly partnerships to mitigate tariff exposure. At the same time, software and cloud subscription models have emerged as less constrained levers for capacity expansion, offering a pathway to sustain access to advanced analysis without direct hardware acquisition. Regulatory scrutiny around dual-use materials and export controls has become more prominent, necessitating tighter compliance workflows for cross-border collaborations. Collectively, the cumulative effect of tariff-driven changes is a reconfiguration of procurement practices, an increase in emphasis on supply chain resilience, and a strategic reassessment of capital versus operational expenditure for research organizations and commercial entities alike.
In-depth segmentation synthesis revealing technique-specific, product-layered, application-focused, end-user-driven, and workflow-oriented dynamics shaping strategic investment decisions
Segment-level dynamics reveal where scientific workflows and commercial strategies intersect, creating differentiated priorities across technique, product type, application, end user, and workflow step. By technique, the landscape spans computational modeling, cryo-electron microscopy, mass spectrometry, NMR spectroscopy, and X-ray crystallography. Computational modeling includes ab initio modeling, homology modeling, and molecular dynamics as critical subdomains that increasingly inform experimental design. Cryo-EM encompasses both single particle analysis and tomography, with single particle routes driving routine structural elucidation and tomography enabling contextual cellular imaging. Mass spectrometry covers ESI and MALDI-TOF approaches, each suited to distinct analyte classes and throughput requirements. NMR spectroscopy divides into solid-state and solution modalities, which together support studies of membrane proteins, fibrils, and soluble complexes. X-ray crystallography continues to operate across powder and single-crystal methods, providing complementary high-resolution information when crystallogenesis is feasible.
Product-type segmentation distinguishes instruments, reagents and consumables, services, and software. Within reagents and consumables, enzymes and kits remain essential for standardized workflows and reproducibility, with kits facilitating method transferability and enzymes enabling tailored experimental chemistries. Applications span biomarker discovery, drug discovery, protein engineering, and structure-function analysis; within drug discovery, lead identification and lead optimization represent sequential needs that combine high-throughput screening with detailed structural interrogation. End users include academic research institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each group exhibiting distinct procurement cycles, validation requirements, and scalability demands. Workflow-step segmentation highlights data collection, data processing, sample preparation, and visualization, where data collection splits into automated and manual collection modalities; automation addresses throughput and reproducibility, while manual approaches retain value for bespoke or atypical samples. Taken together, these segmentation lenses clarify where investments in instrumentation, software, and services will most effectively unlock scientific and commercial value.
Comparative regional analysis showing differentiated adoption curves, manufacturing footprints, and collaborative ecosystems across the Americas, EMEA, and Asia-Pacific
Regional dynamics influence where technologies are adopted, where manufacturing and service hubs concentrate, and how collaborative ecosystems evolve. In the Americas, established academic centers and a mature biotechnology ecosystem create sustained demand for high-end instruments, bespoke reagents, and integrated services, with strong translational pipelines connecting discovery to clinical development. Investment in software platforms and cloud-enabled processing is pronounced, supporting distributed research teams and data-centric collaborations across institutions.
Europe, Middle East & Africa combines centers of excellence in fundamental research with a diverse industrial landscape where regulatory frameworks and public funding models shape procurement cycles. Local manufacturing capacity and regional consortiums often drive collaborative initiatives focused on standardization and technique refinement, while varied regulatory environments necessitate adaptable commercialization strategies and robust compliance frameworks.
Asia-Pacific exhibits rapid expansion in both academic output and industrial R&D, with major hubs investing in cryo-EM facilities, mass spectrometry networks, and computational infrastructure. Domestic manufacturing of instruments and consumables is growing, supported by state-level initiatives and private capital, which together accelerate local access while also fostering export-oriented supply chains. Across all regions, cross-border collaborations and data-sharing agreements are becoming central to complex projects, but regional policy, infrastructure, and talent availability continue to shape distinct adoption curves and partnership models.
Strategic competitive behaviors and innovation pathways among instrument, reagent, software, and service providers that determine market positioning and long-term differentiation
Leading organizations across instrument manufacturing, reagent supply, software development, and service provision are driving innovation through product refinement, strategic partnerships, and expanded service portfolios. Instrument vendors are prioritizing modularity, ease of use, and integrated service agreements to lower adoption barriers for medium-sized laboratories, while reagent suppliers are investing in standardized kits and validated enzyme mixes that accelerate protocol transfer and reproducibility. Service providers and contract research organizations are differentiating through specialized offerings that combine structural determination with downstream functional assays, enabling clients to compress timelines from target validation to lead optimization.
Software firms and computational tool developers are emphasizing interoperability, cloud-native processing, and user-centric interfaces to broaden uptake beyond specialist groups. Partnerships between computational and experimental providers are increasingly common, enabling bundled workflows that offer end-to-end solutions from data acquisition through visualization. Intellectual property practices and collaborative licensing models are evolving to balance open-method dissemination with commercial incentives for tool developers. For organizations seeking competitive advantage, sustained investment in user training, post-sale support, and validated workflows is emerging as a critical differentiator that drives long-term customer retention and scientific impact.
Actionable strategic initiatives for leaders focused on resilience, interoperability, workforce capability, and hybrid service offerings to secure competitive advantage
Industry leaders should prioritize resilience, interoperability, and talent development to remain competitive in the evolving structural biology ecosystem. First, strengthening supply chain flexibility through diversified sourcing and regional partnerships reduces exposure to policy-driven disruptions and short-term shortages. Second, adopting open standards for data formats and APIs enhances interoperability between instruments, processing pipelines, and visualization tools, enabling faster integration of new capabilities and smoother collaboration across institutions. Third, embedding reproducibility into product design-through validated kits, standardized protocols, and accessible training-will accelerate adoption and reduce long-term support burdens.
Additionally, organizations should invest in hybrid offerings that combine experimental services with computational modeling to deliver higher-value, end-to-end solutions for clients focused on drug discovery and protein engineering. Prioritizing workforce development-particularly in data science, software engineering, and multidisciplinary project management-will be essential to execute complex studies and maintain methodological rigor. Finally, proactive engagement with policymakers and standards bodies can shape favorable regulatory outcomes and help align public funding with infrastructure needs, thus creating an environment conducive to sustained innovation and collaboration.
A transparent, mixed-methods research approach combining technical literature, product documentation, and expert interviews to validate workflows and adoption patterns
This research synthesizes primary and secondary evidence, triangulating technical literature, patent filings, vendor product documentation, technique-specific methodology papers, and domain expert interviews to construct a robust view of current capabilities and adoption patterns. Methodologically, the study integrates qualitative inputs from laboratory directors, R&D leads, and service providers with a systematic review of technological roadmaps and peer-reviewed advances in cryo-EM, mass spectrometry, NMR, crystallography, and computational modeling techniques. Emphasis was placed on reproducible workflows, validated protocols, and software interoperability, with cross-checks to ensure alignment between reported capabilities and observed product specifications.
Wherever possible, methodological transparency was maintained through explicit documentation of inclusion criteria for literature sources, interview protocols, and the process used to normalize technical descriptors across subdomains. The study gives special attention to end-user requirements, procurement practices, and workflow bottlenecks observed across academic, biotech, CRO, and pharmaceutical settings. Limitations are acknowledged with respect to rapidly evolving vendor roadmaps and emerging computational models; therefore, recommendations emphasize adaptable strategies that can be revalidated as new evidence emerges.
Conclusions emphasizing the necessity of integration, standardization, and workforce capability to translate structural insights into sustained scientific and commercial impact
The intersection of experimental advances and computational innovation is reshaping what is possible in structural biology and molecular modeling, creating a landscape where integrated workflows and data-centric practices are central to scientific progress. Organizations that align procurement, talent development, and partnership strategies with these trends will be best positioned to convert structural insights into translational outcomes. At the same time, policy changes and supply chain pressures demand proactive responses to maintain operational continuity and to protect R&D investments.
Looking forward, the field will be defined by its ability to harmonize diverse technique modalities, scale reproducible protocols, and sustain multidisciplinary teams capable of navigating complex projects. Delivering on this promise requires deliberate choices around interoperability, standardization, and workforce capability. Those who adopt adaptive procurement models, prioritize validated workflows, and leverage hybrid experimental-computational offerings will accelerate discovery and maintain a competitive edge in a rapidly progressing scientific environment.
Please Note: PDF & Excel + Online Access - 1 Year
A unified overview of how integrated experimental and computational advances are redefining structural biology practice and accelerating translational research outcomes
The structural biology and molecular modeling landscape is undergoing a rapid evolution driven by converging advances in computational power, cryo-electron microscopy, mass spectrometry, nuclear magnetic resonance, and crystallography. Researchers and technology adopters are no longer operating within siloed technique domains; instead, integrated workflows that combine high-resolution imaging, precise mass analysis, and predictive in silico modeling are establishing new norms for how molecular structures are resolved and functionally interpreted. This synthesis of experimental and computational approaches is enabling deeper mechanistic understanding across basic biology, translational research, and therapeutic design.
As academic groups, biotechnology ventures, contract research organizations, and pharmaceutical developers increasingly demand interoperable data and reproducible methods, the pressure to harmonize instrumentation, reagents, software, and standardized workflows is intensifying. The industry is responding with modular platforms, cloud-enabled processing pipelines, and cross-disciplinary teams that accelerate the translation of structural insights into actionable hypotheses. Consequently, leadership in this field now depends as much on data engineering and computational governance as on hardware performance and reagents quality.
How convergent innovations in imaging, analytical chemistry, and predictive computing are reshaping laboratory operations and translational research pipelines
The past several years have witnessed transformative shifts in capabilities and expectations across structural biology and molecular modeling. Advances in single-particle cryo-electron microscopy have simplified access to near-atomic resolution for complex proteins, while improvements in detector sensitivity and sample preparation methods have reduced the barrier to entry for smaller laboratories. Parallel progress in mass spectrometry, including refined ionization techniques and instrument automation, has improved confidence in proteoform identification and post-translational modification mapping. Meanwhile, enhancements in NMR hardware and pulse sequences have broadened the applicability of solution and solid-state analyses for challenging systems.
On the computational side, increased adoption of molecular dynamics, homology modeling, and ab initio prediction tools has shifted many early-stage structural questions into in silico domains, enabling hypothesis generation prior to experimental commitment. Integration across single-particle analysis, tomography, and computational docking has created hybrid workflows that shorten iteration cycles between model and experiment. These shifts are accompanied by organizational changes: multidisciplinary teams that combine wet-lab expertise with data science and software engineering are becoming essential for executing complex projects at scale. Collectively, these developments are changing investment priorities and operational models across academia and industry, and they are elevating the importance of software interoperability, data standards, and reproducible pipelines.
Assessment of how 2025 tariff adjustments have reshaped procurement, supply chain resilience, and strategic sourcing for structural biology stakeholders
Policy changes in tariffs and trade barriers implemented in 2025 have exerted measurable pressure on procurement, supply chain strategies, and capital planning for entities engaged in structural biology and molecular modeling. Increased duties on imported high-value instruments and specialty reagents have prompted manufacturers and distributors to re-evaluate sourcing strategies and pricing models, resulting in longer lead times for certain instrument deliveries and a renewed emphasis on regional supplier diversification. Academic and industry laboratories dependent on specific consumables have had to balance short-term inventory pre-positioning against the operational risk of excess stock, while contract research organizations with thin margins have sought to renegotiate supplier terms or consolidate vendor relationships.
These policy shifts have also accelerated localization initiatives, with some manufacturers expanding regional manufacturing footprints or forging assembly partnerships to mitigate tariff exposure. At the same time, software and cloud subscription models have emerged as less constrained levers for capacity expansion, offering a pathway to sustain access to advanced analysis without direct hardware acquisition. Regulatory scrutiny around dual-use materials and export controls has become more prominent, necessitating tighter compliance workflows for cross-border collaborations. Collectively, the cumulative effect of tariff-driven changes is a reconfiguration of procurement practices, an increase in emphasis on supply chain resilience, and a strategic reassessment of capital versus operational expenditure for research organizations and commercial entities alike.
In-depth segmentation synthesis revealing technique-specific, product-layered, application-focused, end-user-driven, and workflow-oriented dynamics shaping strategic investment decisions
Segment-level dynamics reveal where scientific workflows and commercial strategies intersect, creating differentiated priorities across technique, product type, application, end user, and workflow step. By technique, the landscape spans computational modeling, cryo-electron microscopy, mass spectrometry, NMR spectroscopy, and X-ray crystallography. Computational modeling includes ab initio modeling, homology modeling, and molecular dynamics as critical subdomains that increasingly inform experimental design. Cryo-EM encompasses both single particle analysis and tomography, with single particle routes driving routine structural elucidation and tomography enabling contextual cellular imaging. Mass spectrometry covers ESI and MALDI-TOF approaches, each suited to distinct analyte classes and throughput requirements. NMR spectroscopy divides into solid-state and solution modalities, which together support studies of membrane proteins, fibrils, and soluble complexes. X-ray crystallography continues to operate across powder and single-crystal methods, providing complementary high-resolution information when crystallogenesis is feasible.
Product-type segmentation distinguishes instruments, reagents and consumables, services, and software. Within reagents and consumables, enzymes and kits remain essential for standardized workflows and reproducibility, with kits facilitating method transferability and enzymes enabling tailored experimental chemistries. Applications span biomarker discovery, drug discovery, protein engineering, and structure-function analysis; within drug discovery, lead identification and lead optimization represent sequential needs that combine high-throughput screening with detailed structural interrogation. End users include academic research institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each group exhibiting distinct procurement cycles, validation requirements, and scalability demands. Workflow-step segmentation highlights data collection, data processing, sample preparation, and visualization, where data collection splits into automated and manual collection modalities; automation addresses throughput and reproducibility, while manual approaches retain value for bespoke or atypical samples. Taken together, these segmentation lenses clarify where investments in instrumentation, software, and services will most effectively unlock scientific and commercial value.
Comparative regional analysis showing differentiated adoption curves, manufacturing footprints, and collaborative ecosystems across the Americas, EMEA, and Asia-Pacific
Regional dynamics influence where technologies are adopted, where manufacturing and service hubs concentrate, and how collaborative ecosystems evolve. In the Americas, established academic centers and a mature biotechnology ecosystem create sustained demand for high-end instruments, bespoke reagents, and integrated services, with strong translational pipelines connecting discovery to clinical development. Investment in software platforms and cloud-enabled processing is pronounced, supporting distributed research teams and data-centric collaborations across institutions.
Europe, Middle East & Africa combines centers of excellence in fundamental research with a diverse industrial landscape where regulatory frameworks and public funding models shape procurement cycles. Local manufacturing capacity and regional consortiums often drive collaborative initiatives focused on standardization and technique refinement, while varied regulatory environments necessitate adaptable commercialization strategies and robust compliance frameworks.
Asia-Pacific exhibits rapid expansion in both academic output and industrial R&D, with major hubs investing in cryo-EM facilities, mass spectrometry networks, and computational infrastructure. Domestic manufacturing of instruments and consumables is growing, supported by state-level initiatives and private capital, which together accelerate local access while also fostering export-oriented supply chains. Across all regions, cross-border collaborations and data-sharing agreements are becoming central to complex projects, but regional policy, infrastructure, and talent availability continue to shape distinct adoption curves and partnership models.
Strategic competitive behaviors and innovation pathways among instrument, reagent, software, and service providers that determine market positioning and long-term differentiation
Leading organizations across instrument manufacturing, reagent supply, software development, and service provision are driving innovation through product refinement, strategic partnerships, and expanded service portfolios. Instrument vendors are prioritizing modularity, ease of use, and integrated service agreements to lower adoption barriers for medium-sized laboratories, while reagent suppliers are investing in standardized kits and validated enzyme mixes that accelerate protocol transfer and reproducibility. Service providers and contract research organizations are differentiating through specialized offerings that combine structural determination with downstream functional assays, enabling clients to compress timelines from target validation to lead optimization.
Software firms and computational tool developers are emphasizing interoperability, cloud-native processing, and user-centric interfaces to broaden uptake beyond specialist groups. Partnerships between computational and experimental providers are increasingly common, enabling bundled workflows that offer end-to-end solutions from data acquisition through visualization. Intellectual property practices and collaborative licensing models are evolving to balance open-method dissemination with commercial incentives for tool developers. For organizations seeking competitive advantage, sustained investment in user training, post-sale support, and validated workflows is emerging as a critical differentiator that drives long-term customer retention and scientific impact.
Actionable strategic initiatives for leaders focused on resilience, interoperability, workforce capability, and hybrid service offerings to secure competitive advantage
Industry leaders should prioritize resilience, interoperability, and talent development to remain competitive in the evolving structural biology ecosystem. First, strengthening supply chain flexibility through diversified sourcing and regional partnerships reduces exposure to policy-driven disruptions and short-term shortages. Second, adopting open standards for data formats and APIs enhances interoperability between instruments, processing pipelines, and visualization tools, enabling faster integration of new capabilities and smoother collaboration across institutions. Third, embedding reproducibility into product design-through validated kits, standardized protocols, and accessible training-will accelerate adoption and reduce long-term support burdens.
Additionally, organizations should invest in hybrid offerings that combine experimental services with computational modeling to deliver higher-value, end-to-end solutions for clients focused on drug discovery and protein engineering. Prioritizing workforce development-particularly in data science, software engineering, and multidisciplinary project management-will be essential to execute complex studies and maintain methodological rigor. Finally, proactive engagement with policymakers and standards bodies can shape favorable regulatory outcomes and help align public funding with infrastructure needs, thus creating an environment conducive to sustained innovation and collaboration.
A transparent, mixed-methods research approach combining technical literature, product documentation, and expert interviews to validate workflows and adoption patterns
This research synthesizes primary and secondary evidence, triangulating technical literature, patent filings, vendor product documentation, technique-specific methodology papers, and domain expert interviews to construct a robust view of current capabilities and adoption patterns. Methodologically, the study integrates qualitative inputs from laboratory directors, R&D leads, and service providers with a systematic review of technological roadmaps and peer-reviewed advances in cryo-EM, mass spectrometry, NMR, crystallography, and computational modeling techniques. Emphasis was placed on reproducible workflows, validated protocols, and software interoperability, with cross-checks to ensure alignment between reported capabilities and observed product specifications.
Wherever possible, methodological transparency was maintained through explicit documentation of inclusion criteria for literature sources, interview protocols, and the process used to normalize technical descriptors across subdomains. The study gives special attention to end-user requirements, procurement practices, and workflow bottlenecks observed across academic, biotech, CRO, and pharmaceutical settings. Limitations are acknowledged with respect to rapidly evolving vendor roadmaps and emerging computational models; therefore, recommendations emphasize adaptable strategies that can be revalidated as new evidence emerges.
Conclusions emphasizing the necessity of integration, standardization, and workforce capability to translate structural insights into sustained scientific and commercial impact
The intersection of experimental advances and computational innovation is reshaping what is possible in structural biology and molecular modeling, creating a landscape where integrated workflows and data-centric practices are central to scientific progress. Organizations that align procurement, talent development, and partnership strategies with these trends will be best positioned to convert structural insights into translational outcomes. At the same time, policy changes and supply chain pressures demand proactive responses to maintain operational continuity and to protect R&D investments.
Looking forward, the field will be defined by its ability to harmonize diverse technique modalities, scale reproducible protocols, and sustain multidisciplinary teams capable of navigating complex projects. Delivering on this promise requires deliberate choices around interoperability, standardization, and workforce capability. Those who adopt adaptive procurement models, prioritize validated workflows, and leverage hybrid experimental-computational offerings will accelerate discovery and maintain a competitive edge in a rapidly progressing scientific environment.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of generative artificial intelligence models for de novo protein design in therapeutic development pipelines
- 5.2. Advancements in cryo-electron microscopy data processing enabling near-atomic resolution structure determination for challenging membrane proteins
- 5.3. Development of hybrid modeling approaches combining NMR spectroscopy and small-angle X-ray scattering for dynamic macromolecular assembly characterization
- 5.4. Adoption of cloud-based high-performance computing platforms for large-scale molecular dynamics simulations in biopharmaceutical research
- 5.5. Emergence of machine learning-guided ligand docking algorithms for accelerated target-based drug screening and lead optimization
- 5.6. Implementation of integrative structural biology workflows using artificial intelligence to model protein–protein interaction networks at scale
- 5.7. Incorporation of time-resolved cryo-EM techniques to capture transient conformational states in enzymatic reaction mechanisms
- 5.8. Utilization of quantum computing-inspired algorithms for enhanced sampling in complex biomolecular systems and energy landscape exploration
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Structural Biology & Molecular Modeling Techniques Market, by Technique
- 8.1. Computational Modeling
- 8.1.1. Ab Initio Modeling
- 8.1.2. Homology Modeling
- 8.1.3. Molecular Dynamics
- 8.2. Cryo-Em
- 8.2.1. Single Particle Analysis
- 8.2.2. Tomography
- 8.3. Mass Spectrometry
- 8.3.1. Esi
- 8.3.2. Maldi-Tof
- 8.4. Nmr Spectroscopy
- 8.4.1. Solid State Nmr
- 8.4.2. Solution Nmr
- 8.5. X-Ray Crystallography
- 8.5.1. Powder
- 8.5.2. Single-Crystal
- 9. Structural Biology & Molecular Modeling Techniques Market, by Product Type
- 9.1. Instruments
- 9.2. Reagents And Consumables
- 9.2.1. Enzymes
- 9.2.2. Kits
- 9.3. Services
- 9.4. Software
- 10. Structural Biology & Molecular Modeling Techniques Market, by Workflow Step
- 10.1. Data Collection
- 10.1.1. Automated Collection
- 10.1.2. Manual Collection
- 10.2. Data Processing
- 10.3. Sample Preparation
- 10.4. Visualization
- 11. Structural Biology & Molecular Modeling Techniques Market, by Application
- 11.1. Biomarker Discovery
- 11.2. Drug Discovery
- 11.2.1. Lead Identification
- 11.2.2. Lead Optimization
- 11.3. Protein Engineering
- 11.4. Structure Function Analysis
- 12. Structural Biology & Molecular Modeling Techniques Market, by End User
- 12.1. Academic Research Institutes
- 12.2. Biotechnology Companies
- 12.3. Contract Research Organizations
- 12.4. Pharmaceutical Companies
- 13. Structural Biology & Molecular Modeling Techniques Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Structural Biology & Molecular Modeling Techniques Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Structural Biology & Molecular Modeling Techniques Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Dassault Systèmes SE
- 16.3.2. Schrödinger, Inc.
- 16.3.3. OpenEye Scientific Software, Inc.
- 16.3.4. Chemical Computing Group ULC
- 16.3.5. Cresset Group Limited
- 16.3.6. BioSolveIT GmbH
- 16.3.7. Moleculon, Inc.
- 16.3.8. NanoTemper Technologies GmbH
- 16.3.9. Genedata AG
- 16.3.10. Compugen Ltd.
- 16.3.11. Simulations Plus, Inc.
- 16.3.12. Certara, L.P.
- 16.3.13. Cyclica Inc.
- 16.3.14. Nimbus Therapeutics, Inc.
- 16.3.15. Relay Therapeutics, Inc.
- 16.3.16. Atomwise Inc.
- 16.3.17. Biosym Technologies
- 16.3.18. Cresset BioMolecular Discovery Ltd.
- 16.3.19. Molsoft LLC
- 16.3.20. Tripos International
- 16.3.21. Cytiva
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
